BioNTech to Present Pivotal Pumitamig NSCLC and Autogene Cevumeran Pancreatic Cancer Data at ASCO 2026

On May 22, 2026, BioNTech announced it will showcase its late-stage oncology pipeline at the 2026 ASCO Annual Meeting in Chicago (May 29–June 2, 2026). The centerpiece presentation is interim Phase 2/3 ROSETTA Lung-02 data for pumitamig — an mRNA immunotherapy — in first-line non-small cell lung cancer (NSCLC) across PD-L1 expression levels and squamous/non-squamous subtypes. BioNTech has launched five new pivotal trials for pumitamig in 2026 spanning triple-negative breast cancer, MSS colorectal, gastric cancer, and two additional NSCLC settings. Also featured: six-year follow-up data for autogene cevumeran (BNT122), the individualized mRNA neoantigen vaccine for pancreatic ductal adenocarcinoma (PDAC), co-developed with Genentech. The AACR 2026-presented Phase 1 data showed approximately 87.5% of immune responders (7 of 8) still alive at six-year follow-up — an extraordinary outcome for a cancer type with an overall 5-year survival rate of ~13%. Phase 2 randomized trial NCT05968326 is now enrolling at dozens of sites globally. BioNTech has 13 ongoing pivotal trials and a $19.6B cash position, supporting its expanded Phase 2/3 cancer vaccine program through expected readouts in late 2026 and 2027. The stock has been near year lows as markets await pumitamig NSCLC data as a pivotal test of BioNTech's oncology pivot.